Skip to main content

Aardvark Therapeutics, Inc.

AARD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001774857

In the last 90 days, Aardvark Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 71 institutions reported holding it in 13F filings for Q2 2026, worth $54.3M in total; no superinvestor holds it.

Holders of 5% or more of AARD

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Aardvark Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of AARD
HolderLatest formStakeChangeFirst filedLatest filingFiling
Decheng Capital Global Life Sciences Fund IV, L.P.13G18.30%3.92M sharesNewFeb 24, 20251 filingFeb 24, 2025SEC
Lee Tien-Li13G13.70%2.98M sharesNewMay 15, 20251 filingMay 15, 2025SEC
Tan Finian13G9.58%2.05M sharesNewFeb 24, 20251 filingFeb 24, 2025SEC
Citadel Advisors LLC13G5.60%1.19M sharesNewFeb 24, 20251 filingFeb 24, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

4 Schedule 13D and 13G filings on Aardvark Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on AARD
Filed (ET)FilerFormStakeChangeEvent dateFiling
May 15, 20254:52 PM ETLee Tien-Liand 1 other13G13.70%2.98M sharesNewMar 31, 2025SEC
Feb 24, 20255:55 PM ETCitadel Advisors LLCand 6 others13G5.60%1.19M sharesNewFeb 14, 2025SEC
Feb 24, 20254:16 PM ETDecheng Capital Global Life Sciences Fund IV, L.P.and 4 others13G18.30%3.92M sharesNewFeb 14, 2025SEC
Feb 24, 20257:00 AM ETTan Finianand 2 others13G9.58%2.05M sharesNewFeb 12, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Aardvark Therapeutics, Inc. shares.

No Form 144 notices for Aardvark Therapeutics, Inc. are on file.